Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycin's First of Two Phase 3 Pneumonia Trials

CHICAGO, June 29, 2007 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. , today announced that it will host a conference call and live webcast at 10:00 am (EDT) on Monday, July 2, 2007 to discuss data from Trial CL-06, the first of two pivotal Phase 3 clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day antibiotic, for the treatment of community acquired pneumonia (CAP).

Conference Call Details:

The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of the Advanced Life Sciences corporate website http://www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 800-561-2601(domestic) or 617-614-3518 (international). The passcode for the conference call is 84510433. A replay of the conference call will be available until August 2, 2007. Callers may access the telephone replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 90055877.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, clinical trials, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

CONTACT: Joe Camp of Advanced Life Sciences Holdings, Inc.,+1-630-754-4352

Web site: http://www.advancedlifesciences.com/

Ticker Symbol: (NASDAQ-NMS:ADLS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: June 2007

View comments

Hide
(web4)